WASHINGTON, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

         Date of report (Date of earliest event reported): June 18, 2001
                               CYTOGEN CORPORATION
               (Exact Name of Registrant as Specified in Charter)

         Delaware                     000-14879                  222322400
------------------------------  ------------------------     -------------------
(State or Other                 (Commission File Number)      (I.R.S. Employer
Jurisdiction of Incorporation)                               Identification No.)

    600 College Road East, CN 5308, Princeton, NJ                   08540
--------------------------------------------------------     -------------------
     (Address of Principal Executive Offices)                    (Zip Code)

       Registrant's telephone number, including area code: (609) 750-8200


     On March  28,  2000,  Cytogen  Corporation,  a  Delaware  corporation  (the
"Company")   filed  a  registration   statement   (File  No.   333-33436)   (the
"Registration   Statement")  on  Form  S-3  with  the  Securities  and  Exchange
Commission (the "Commission") relating to the public offering,  pursuant to Rule
415 under the Securities Act of 1933, as amended (the  "Securities  Act"), of up
to an aggregate of 6,000,000  shares of common stock of the Company.  On June 9,
2000, the Company filed  Amendment No. 1 to the  Registration  Statement on Form
S-3/A with the Commission.  The Commission  declared the Registration  Statement
effective on June 14, 2000.

     On June 18, 2001, the Company entered into a Share Purchase  Agreement (the
"Agreement")  with the State of Wisconsin  Investment Board ("SWIB") relating to
the issuance and sale of 1,820,000  shares of the Company's  Common Stock for an
aggregate purchase price of approximately $8.2 million.

     On June 19, 2001,  the Company  filed with the  Commission a prospectus  as
part  of the  Registration  Statement  and  pursuant  to Rule  424(b)(2)  of the
Securities  Act,  relating to the sale of such shares and issued the shares upon
closing of the  transaction.  Upon the issuance of such  shares,  all except 842
shares registered under the Registration Statement have been issued.

     In connection  with its execution of the  Agreement,  the Company agreed to
discontinue the use of its Equity Financing Facility with Acqua Wellington North
American Equities Fund, Ltd. The Company further agreed to amend,  within thirty
days of  closing,  its Bylaws and its stock  option  plans,  as set forth in the
Agreement, to prohibit,  without requisite stockholder approval,  certain option
grants or option adjustments,  the sale of certain securities of the Company and
the execution of certain equity line or future priced securities arrangements.

     Each of the  Agreement  and the related  press release of the Company dated
June 18, 2001 are attached hereto as Exhibits 10.1 and 99.1,  respectively,  and
are incorporated herein by reference.


         (a)  Exhibits.

              Exhibit No.   Description
              -----------   -----------

                 10.1       Share Purchase Agreement
                 99.1       Press release dated June 18, 2001


     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly caused this current  report on Form 8-K to be signed on its
behalf by the undersigned hereunto duly authorized.

                                          CYTOGEN CORPORATION

                                          By: /s/ Catherine M. Verna
                                              Catherine M. Verna, Esq.
                                              Vice President and General Counsel

Dated:      June 19, 2001

                                  EXHIBIT INDEX

              Exhibit No.   Description
              -----------   -----------

                 10.1       Share Purchase Agreement
                 99.1       Press release dated June 18, 2001